ASLAN Pharmaceuticals Stock Set to Reverse Split on Wednesday, July 3rd (NASDAQ:ASLN)

ASLAN Pharmaceuticals Limited (NASDAQ:ASLNFree Report) shares are scheduled to reverse split before the market opens on Wednesday, July 3rd. The 1-8 reverse split was announced on Wednesday, July 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, July 3rd.

ASLAN Pharmaceuticals Price Performance

ASLAN Pharmaceuticals stock opened at $0.31 on Tuesday. The company has a market capitalization of $5.10 million, a P/E ratio of -0.11 and a beta of 1.44. The stock’s 50 day moving average is $0.43 and its 200 day moving average is $0.53. ASLAN Pharmaceuticals has a twelve month low of $0.31 and a twelve month high of $3.90.

ASLAN Pharmaceuticals (NASDAQ:ASLNGet Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.61). As a group, equities analysts expect that ASLAN Pharmaceuticals will post -2.55 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of ASLAN Pharmaceuticals in a research note on Friday, May 3rd. Piper Sandler reiterated an “overweight” rating and set a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

Check Out Our Latest Report on ASLN

ASLAN Pharmaceuticals Company Profile

(Get Free Report)

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.

Read More

Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with's FREE daily email newsletter.